Genomic Health (GHDX) Prelim. Q4, FY15 Revenues Miss Expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Dell shares surge on record AI server bookings
- 'No panic anywhere' may be the problem, BofA strategists warn
- Kroger cuts same-store sales outlook, keeps earnings guidance
- AstraZeneca's camizestrant fails primary endpoint in breast cancer trial
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Genomic Health Announces Preliminary 2015 Revenue and Confirms 2016 Growth Expectations
January 8, 2016 8:00 AM ESTREDWOOD CITY, Calif., Jan. 8, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced preliminary revenue for the year ended December 31, 2015, is expected to be between $285 and $286 million, compared with $275.7 million in 2014, representing an increase of approximately 4 percent, slightly below the Company's 2015 guidance.
The Company delivered more than 106,850 Oncotype DX® tests in 2015, an increase of approximately 12 percent compared with 2014, within the Company's 2015 guidance.Â
For the fourth quarter 2015, the Company anticipates reporting between $73 and $74 million in revenue, representing an increase of approximately 6 percent compared to the fourth quarter of 2014, and more than... More
